WO2012062109A1 - 阿利克仑的药物中间体的制备方法 - Google Patents
阿利克仑的药物中间体的制备方法 Download PDFInfo
- Publication number
- WO2012062109A1 WO2012062109A1 PCT/CN2011/075800 CN2011075800W WO2012062109A1 WO 2012062109 A1 WO2012062109 A1 WO 2012062109A1 CN 2011075800 W CN2011075800 W CN 2011075800W WO 2012062109 A1 WO2012062109 A1 WO 2012062109A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reaction
- aliskiren
- hexane
- product
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
Definitions
- the invention relates to the field of medicine, in particular to a preparation method of an anti-hypertensive drug aliskiren intermediate.
- Cardiovascular diseases including high blood pressure, are the number one death factor in the world and are known as "the number one executioner of human health.”
- the listed antihypertensive drugs are mainly divided into the following categories: diuretics (thiazide drugs), ⁇ -blockers (lords), calcium antagonists (prime drugs), vascular tension Invertase inhibitors (Pulis), angiotensin II receptor antagonists (sartans).
- diuretics thiazide drugs
- ⁇ -blockers lords
- calcium antagonists primary drugs
- Pulis vascular tension Invertase inhibitors
- angiotensin II receptor antagonists sartans.
- Aliskiren the first non-peptide renin inhibitor approved by the US FDA in 2007, reduces the levels of angiotensin I and angiotensin II in the body by inhibiting the activity of renin. Blood vessels and blood pressure lowering effects.
- renin activity which is not only a risk factor for myocardial infarction in hypertensive patients, but also closely related to target organ damage, reducing the protective effect of PRA on target organs. This is also an important feature distinguishing renin inhibitors from other antihypertensive drugs.
- the object of the present invention is to provide A novel method for synthesizing intermediates I and II, which eliminates column chromatography, is easy to industrialize, and has high product purity, and is beneficial for subsequent format reaction to produce a product of higher purity.
- the molar ratio of the compound III or IV to the phosphorus bromophosphine oxide is preferably 1:1.0 1:1.2.
- the above reaction is preferably carried out in an aprotic solvent.
- the aprotic solvent is preferably a ketone, an ester, an aromatic hydrocarbon, a halogenated alkane, acetonitrile, dimethyl sulfoxide, N.N-dimethylformamide or the like. More preferably, it is a mixture of toluene, N.N-dimethylformamide, acetonitrile, dichloromethane, chloroform, ethyl acetate, dimethyl sulfoxide, acetone, benzene or a mixture of any two. Most preferred are toluene and / or N.N dimethylformamide.
- the reaction temperature is preferably 20 to 80 °C.
- the above reaction step further includes post-treatment of the reactant, adding 1-3 times the volume of the reaction solvent to the reaction liquid, extracting with n-hexane or petroleum ether, discarding the aqueous phase, and concentrating the organic phase.
- the extraction of n-hexane or petroleum ether can be carried out 1-3 times.
- the organic phase is also preferably washed with saturated sodium bicarbonate and saturated sodium chloride, respectively.
- the organic layer can also be dried over anhydrous sodium sulfate.
- the concentrate is preferably recrystallized from an organic solvent after drying, and the organic solvent is preferably a mixed solvent of methanol or ethyl acetate/n-hexane.
- the concentrate can be directly distilled under reduced pressure.
- the preparation method of the invention removes the prior art by column chromatography to obtain the compounds I and II, and the prior art is difficult to carry out large-scale industrial production, and the invention can directly obtain the product by recrystallization or vacuum distillation, and the product chemistry Good purity.
- the raw materials III or IV are difficult to react completely, which affects the product yield, and the yield is only about 50% to 60%.
- the raw materials are completely reacted, the product yield is high, and the yield can reach 80%. about.
- the product obtained by the invention has high chiral purity and does not undergo racemization during the reaction. detailed description
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/884,408 US9079839B2 (en) | 2010-11-09 | 2011-06-16 | Methods for preparation of pharmaceutical intermediates of aliskiren |
CA2816464A CA2816464C (en) | 2010-11-09 | 2011-06-16 | Methods for preparation of pharmaceutical intermediates of aliskiren |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010535822 CN102001920B (zh) | 2010-11-09 | 2010-11-09 | 一种药物中间体的制备方法 |
CN201010535822.1 | 2010-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012062109A1 true WO2012062109A1 (zh) | 2012-05-18 |
Family
ID=43809663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2011/075800 WO2012062109A1 (zh) | 2010-11-09 | 2011-06-16 | 阿利克仑的药物中间体的制备方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9079839B2 (zh) |
CN (1) | CN102001920B (zh) |
CA (1) | CA2816464C (zh) |
WO (1) | WO2012062109A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102001920B (zh) * | 2010-11-09 | 2013-05-15 | 常州制药厂有限公司 | 一种药物中间体的制备方法 |
CN102757318B (zh) * | 2011-04-29 | 2015-06-24 | 上海医药工业研究院 | 一种阿利克伦中间体的制备方法 |
CN103351300A (zh) * | 2013-06-30 | 2013-10-16 | 北京万全德众医药生物技术有限公司 | 一种制备阿利克仑中间体侧链(s)-2-溴代异戊酸甲酯的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102001920A (zh) * | 2010-11-09 | 2011-04-06 | 常州制药厂有限公司 | 一种药物中间体的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
ITMI20062208A1 (it) * | 2006-11-16 | 2008-05-17 | F I S Fabbrica Italiana Sintetici Spa | Processo per la preparazione di imatinib e suoi intermedi |
-
2010
- 2010-11-09 CN CN 201010535822 patent/CN102001920B/zh active Active
-
2011
- 2011-06-16 WO PCT/CN2011/075800 patent/WO2012062109A1/zh active Application Filing
- 2011-06-16 CA CA2816464A patent/CA2816464C/en active Active
- 2011-06-16 US US13/884,408 patent/US9079839B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102001920A (zh) * | 2010-11-09 | 2011-04-06 | 常州制药厂有限公司 | 一种药物中间体的制备方法 |
Non-Patent Citations (2)
Title |
---|
"Process for Preparation of (2S, 4S, 5S, 7S)-5-Amino-N-(2-Carbamoyl-2-Methyl-Propyl)-4-Hydroxy-7-{ [4-Methoxy-3-(3- Methoxypropoxy)Phenyl]Methyl{-8-Methyl-2-Propan-2-yl-Nonanamide and Intermediates Thereof.", IP.COM JOURNAL., 21 April 2009 (2009-04-21) * |
RICHARD G ET AL.: "The Nonchiral Bislactim Diethoxy Ether as a Highly Stereo-Inducing Synthon for Sterically Hindered, Y -Branched a -Amino Acids: A Practical, Large-Scale Route to an Intermediate of the Novel Renin Inhibitor Aliskiren.", HELVETICA CHIMICAACTA., vol. 86, 2003, pages 2848 - 2870 * |
Also Published As
Publication number | Publication date |
---|---|
US9079839B2 (en) | 2015-07-14 |
CN102001920A (zh) | 2011-04-06 |
US20130231509A1 (en) | 2013-09-05 |
CA2816464C (en) | 2015-02-03 |
CN102001920B (zh) | 2013-05-15 |
CA2816464A1 (en) | 2012-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2190804B1 (en) | Process and intermediates for preparing integrase inhibitors | |
WO2014036823A1 (zh) | 一种新的抗血栓药物的制备方法 | |
Li et al. | An efficient enantioselective synthesis of florfenicol via a vanadium-catalyzed asymmetric epoxidation | |
CN112062712A (zh) | 一种2-(5-溴-3-甲基吡啶-2-基)乙酸盐酸盐的制备方法 | |
WO2008078482A1 (ja) | アセナピン合成中間体の製造方法 | |
WO2012062109A1 (zh) | 阿利克仑的药物中间体的制备方法 | |
CN105622538B (zh) | 一锅法高收率制备新利司他 | |
RU2709493C1 (ru) | Способ получения роксадустата | |
CN103073525A (zh) | 一种合成制备(s)-(3,4-二氟苯基)环氧己烷的方法 | |
TWI500596B (zh) | 合成3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-甲腈之方法,及於合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之應用 | |
Katritzky et al. | Functionalized Naphthalenes by Benzotriazole-Mediated Annulation | |
KR20170070037A (ko) | 할로-치환된 트리플루오로아세토페논의 제조 방법 | |
CN106631867A (zh) | 一种合成2‑苯甲酰胺‑3‑芳基丙烯酸酯的方法 | |
CN103539639B (zh) | 一种药物关键中间体的制备方法 | |
CN113845541B (zh) | 一种制备维生素d3类似物的方法 | |
JP4258658B2 (ja) | アセチレン化合物の製造方法 | |
KR100911720B1 (ko) | 결정형 염산 사포그릴레이트의 제조방법 | |
CN106748853A (zh) | 一种(s)‑邻氯苯甘氨酸甲酯盐酸盐的制备方法 | |
CN108203396A (zh) | 一种脑啡肽酶抑制剂的合成 | |
WO2014147464A2 (en) | Novel process for the preparation of tolcapone | |
WO2008152514A2 (en) | Process for the preparation of alfuzosin and salts thereof | |
KR101519011B1 (ko) | 비스무트 촉매를 이용한 피라노쿠마린 유도체의 제조방법 | |
CN114805029A (zh) | 25-羟基二氢速甾醇关键中间体的有关物质及其制备方法 | |
KR100863463B1 (ko) | 광학적으로 순수한 옥소라이보스유도체의 제조방법 | |
KR101060670B1 (ko) | 라미프릴의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11840521 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2816464 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13884408 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11840521 Country of ref document: EP Kind code of ref document: A1 |